- Home
- TRI vs RVMD Comparison
TRI vs RVMD Comparison
Compare TRI & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRI | RVMD |
|---|---|---|
| Founded | 1851 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.0B | 40.3B |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TRI | RVMD |
|---|---|---|
| Price | $112.76 | $194.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 25 |
| Target Price | $126.88 | ★ $258.84 |
| AVG Volume (30 Days) | 1.7M | ★ 1.9M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.32 | N/A |
| Revenue Next Year | $8.50 | $526.64 |
| P/E Ratio | $25.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $76.28 | $61.50 |
| 52 Week High | $142.04 | $224.31 |
Technical Indicators
Market Signals| Indicator | TRI | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.62 | 50.85 |
| Support Level | $81.19 | $177.62 |
| Resistance Level | $124.69 | $197.29 |
| Average True Range (ATR) | 4.85 | 10.15 |
| MACD | -0.63 | 0.62 |
| Stochastic Oscillator | 33.82 | 47.04 |
Price Performance
Historical ComparisonAbout TRI Thomson Reuters Corp
Thomson Reuters is a leading global provider of business information services, delivering trusted data, technology, and expertise to professionals across legal, tax, accounting, risk, compliance, and the news and media sectors. Headquartered in Toronto, Canada, the company combines deep domain knowledge with data and software solutions to help clients make informed decisions, manage complexity, and drive efficiency. Thomson Reuters serves legal and accounting/tax professionals, corporations, and governments worldwide, but around 75% of revenue is generated in the US. The company is known for flagship products such as Westlaw, UltraTax CS, and Reuters News.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.